Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women

Breast Cancer Research

Volumn 6, Issue 6, 2004, Pages

  Friedrichsen, Danielle M ^a   Malone, Kathleen E ^a,b   Doody, David R ^a   Daling, Janet R ^a,b   Ostrander, Elaine A ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Breast cancer; Case control study; CHEK2; Population based

Indexed keywords

CHECKPOINT KINASE 2; PROTEIN SERINE THREONINE KINASE;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FAMILY HISTORY; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; POPULATION RESEARCH; PROTEIN FUNCTION; TUMOR SUPPRESSOR GENE; BREAST TUMOR; ENZYMOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MUTATION;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; PROTEIN-SERINE-THREONINE KINASES;

EID: 21644484444     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr933     Document Type: Article

References (26)

1. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C: The human homologs of checkpoint kinases Chk1 and Cds1 phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 2000, 14: 289-300.
2. Bartek J, Falck J, Lukas J: CHK2 kinase: a busy messenger. Nat Rev Mol Cell Biol. 2001, 2: 877-886. 10.1038/35103059.
3. Seppala EH, Ikonen T, Mononen N, Autio V, Rokman A, Matikainen MP, Tammela TL, Schleutker J: CHEK2 variants associate with hereditary prostate cancer. Br J Cancer. 2003, 89: 1966-1970. 10.1038/sj.bjc.6601425.
4. Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ, et al: Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet. 2003, 72: 270-280. 10.1086/346094.
5. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, et al: Low-penetrance susceptibility to breast cancer due to CHEK21100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002, 31: 55-59. 10.1038/ng879.
6. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, et al: A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002, 71: 432-438. 10.1086/341943.
7. Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG, Hoogerbrugge N, Ligtenberg MJ, van Asperen CJ, Vasen HF, Meijers C, et al: The CHEK21100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res. 2003, 63: 8153-8157.
8. Offit K, Pierce H, Kirchhoff T, Kolachana P, Rapaport B, Gregersen P, Johnson S, Yossepowitch O, Huang H, Satagopan J, et al: Frequency of CHEK21100delC in New York breast cancer cases and controls. BMC Med Genet. 2003, 4: 1. 10.1186/1471-2350-4-1.
9. Allinen M, Huusko P, Mantyniemi S, Launonen V, Winqvist R: Mutation analysis of the CHK2 gene in families with hereditary breast cancer. Br J Cancer. 2001, 85: 209-212. 10.1054/bjoc.2001.1858.
10. Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG, Eccles D, Meijers C, Lohman F, Klijn J, et al: Variants in CHEK21100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet. 2003, 72: 1023-1028. 10.1086/373965.
11. Osorio A, Rodriguez-Lopez R, Diez O, de la Hoya M, Ignacio Martinez J, Vega A, Esteban-Cardenosa E, Alonso C, Caldes T, Benitez J: The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population. Int J Cancer. 2004, 108: 54-56. 10.1002/ijc.11414.
12. Rajkumar T, Soumittra N, Nancy NK, Swaminathan R, Sridevi V, Shanta V: BRCA1, BRCA2 and CHEK2 germline mutations in hereditary breast and ovarian cancer families in South India. Asian Pac J Cancer Prev. 2003, 4: 203-208.
13. Brinton LA, Daling JR, Liff JM, Schoenberg JB, Malone KE, Stanford JL, Coates RJ, Gammon MD, Hanson L, Hoover RN: Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst. 1995, 87: 827-835.
14. Daling JR, Malone KE, Voigt LF, White E, Weiss NS: Risk of breast cancer among young women: relationship to induced abortion. J Natl Cancer Inst. 1994, 86: 1584-1592. 10.1093/jnci/86.21.1584.
15. Waksberg J: Sample methods for random digit dialing. J Am Stat Soc. 1978, 73: 40-46.
16. Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomaki K, Nevanlinna H: p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res. 2001, 61: 5718-5722.
17. Breslow NE, Day NE: Statistical Methods in Cancer Research. The Analysis of Case-control Studies. 1980, Lyon: IARC Scientific Publications, I
18. Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV, Ostrander EA: BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA. 1998, 279: 922-929. 10.1001/jama.279.12.922.
19. Malone KE, Daling JR, Neal C, Suter NM, O'Brien C, Cushing-Haugen K, Jonasdottir TJ, Thompson JD, Ostrander EA: Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer. 2000, 88: 1393-1402. 10.1002/1097-014288:6<1393::AID-CNCR17>3.0.CO;2-P.
20. Wu X, Webster SR, Chen J: Characterization of tumor-associated Chk2 mutations. J Biol Chem. 2001, 276: 2971-2974. 10.1074/jbc.M009727200.
21. Li J, Williams BL, Haire LF, Goldberg M, Wilker E, Durocher D, Yaffe MB, Jackson SP, Smerdon SJ: Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol Cell. 2002, 9: 1045-1054. 10.1016/S1097-276500527-0.
22. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J: The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature. 2001, 410: 842-847. 10.1038/35071124.
23. Broeks A, de Witte L, Nooijen A, Huseinovic A, Klijn JG, van Leeuwen FE, Russell NS, van't Veer LJ: Excess risk for contralateral breast cancer in CHEK21100delC germline mutation carriers. Breast Cancer Res Treat. 2004, 83: 91-93. 10.1023/B:BREA.0000010697.49896.03.
24. Syrjakoski K, Kuukasjarvi T, Auvinen A, Kallioniemi OP: CHEK21100delC is not a risk factor for male breast cancer population. Int J Cancer. 2004, 108: 475-476. 10.1002/ijc.11384.
25. Neuhausen S, Dunning A, Steele L, Yakumo K, Hoffman M, Szabo C, Tee L, Baines C, Pharoah P, Goldgar D, Easton D: Role of CHEK21100delC in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer. 2004, 108: 477-478. 10.1002/ijc.11385.
26. Ohayon T, Gal I, Baruch RG, Szabo C, Friedman E: CHEK21100delC and male breast cancer risk in Israel. Int J Cancer. 2004, 108: 479-480. 10.1002/ijc.11603.